Accuray Incorp Stock Price, News & Analysis

Accuray (NASDAQ: ARAY) reported its Q4 and fiscal 2025 results with mixed performance. Q4 revenue decreased 5% to $127.5 million, while full-year revenue grew 3% to $458.5 million. The company posted Q4 net income of $1.1 million compared to $3.4 million in the prior year, while recording a full-year net loss of $1.6 million, improved from a $15.5 million loss in FY24.

Service revenue showed strength with a 4% increase in both Q4 and full-year results. The company successfully completed a debt refinancing and maintained a book-to-bill ratio of 1.2. For FY26, Accuray projects revenue between $471-485 million and adjusted EBITDA of $31-35 million.

Accuray (NASDAQ: ARAY) has scheduled its fourth quarter fiscal 2025 financial results conference call for August 13, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The company will provide financial results for the quarter ended June 30, 2025.

Investors can access the call through U.S. dial-in (1-888-999-5318) or international dial-in (1-848-280-6460). A replay will be available for one week after the call. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q1 fiscal 2026 results.

Accuray (NASDAQ: ARAY) announced a significant financial restructuring, including the exchange of $82.0 million in convertible notes for 8,881,579 shares of common stock plus $68.6 million in cash. The company secured new credit facilities with TCW Asset Management Company totaling $190 million, comprising a $150 million term loan, $20 million delayed draw facility, and $20 million revolving credit facility. The financing includes the issuance of warrants for approximately 23.4 million shares. As part of the agreement, TCW gains board representation, with Steven F. Mayer joining Accuray's Board of Directors. The new financing structure aims to enhance liquidity and operational flexibility, with proceeds being used to refinance existing debt. Interest rates on the facilities range from SOFR plus 8.50% to base rate plus 7.50%, with partial PIK options.

Accuray (NASDAQ: ARAY), a radiation therapy solutions provider, announces its participation in the Jefferies Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on June 4th, 2025, at 5:30pm EDT/2:30pm PDT. The presentation will be accessible via live webcast through Accuray's Investor Relations website, with replay available for 90 days. Accuray, headquartered in Madison, Wisconsin, specializes in developing innovative radiation therapy solutions for oncology and neuro-radiosurgery, focusing on both complex and routine treatment cases to enhance patient care delivery.

Accuray (NASDAQ: ARAY) presented new clinical data at ESTRO 2025 highlighting the effectiveness of its CyberKnife System for prostate cancer treatment. The studies showcased two significant findings: First, a retrospective analysis of 262 high-risk prostate cancer patients over 70 showed favorable outcomes with low toxicity rates after receiving 5-session SBRT treatments. Second, an early analysis of 51 patients demonstrated the system's effectiveness in treating recurrent cancer post-prostatectomy with mild toxicity. The company hosted a symposium attended by 350 healthcare professionals focusing on genitourinary radiotherapy advancements. The data reinforces CyberKnife's capability to deliver precise, non-invasive treatment in shorter courses, expanding treatment options for prostate cancer patients.

Accuray (NASDAQ: ARAY) announced the first patient treatments with the CyberKnife® System in Austria at the CyberKnife® Center Salzburg. The center utilized Accuray's CyberComm™ technology to commission their latest-generation CyberKnife S7™ System, reducing commissioning time by approximately 50%. The system delivers ultra-hypofractionated radiation therapy in just 1-5 outpatient sessions, compared to conventional 30-40 sessions, with sub-millimeter accuracy.

This installation is particularly significant as Austria's radiotherapy equipment supply is 27% lower than the EU average and 34% lower than economic peers, while cancer cases are projected to increase by 25% between 2022 and 2040. The CyberKnife System's introduction aims to address this healthcare gap and provide more efficient cancer treatment options for Austrian patients.

Accuray reported its fiscal 2025 third quarter results, showing notable improvements in financial performance. The company achieved total net revenue of $113.2 million, marking a 12% increase year-over-year. The quarter saw reduced losses, with net loss decreasing to $1.3 million compared to $6.3 million in the prior year.

Key financial highlights include:

• Product revenue increased 16% to $57.3 million
• Service revenue grew 9% to $55.9 million
• Adjusted EBITDA improved to $6.0 million from $1.1 million
• Cash position strengthened to $78.8 million

Despite facing tariff challenges, the company maintained resilient performance. However, order backlog decreased 10% to $452.4 million. For fiscal year 2025, Accuray reaffirmed its adjusted EBITDA guidance of $28.5-31.0 million but adjusted revenue guidance to $452-460 million due to tariff impacts on product volume.

Accuray (NASDAQ: ARAY) has announced it will release its third quarter fiscal 2025 financial results on April 30, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results for the quarter ended March 31, 2025.

Investors can access the conference call via USA dial-in (1-833-316-0563) or international dial-in (1-412-317-5747). A replay will be available for one week through 1-877-344-7529 (USA) or 1-412-317-0088 (international) using conference ID 8141169. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q4 FY2025 results announcement.

Accuray (NASDAQ: ARAY) presented new clinical data for its CyberKnife® System at the 2025 Radiosurgery Society Scientific Meeting, demonstrating its effectiveness in treating central nervous system tumors. Key findings include:

- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments

- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases

- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination

- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief

The CyberKnife System utilizes image guidance during treatment, leveraging up to 1,000 different beam angles and Synchrony® adaptive delivery technology to adjust for tumor or patient motion in real-time.